MCT1-mediated transport of a toxic molecule is an effective strategy for targeting glycolytic tumors

There is increasing evidence that oncogenic transformation modifies the metabolic program of cells. A common alteration is the upregulation of glycolysis, and efforts to target glycolytic enzymes for anticancer therapy are under way. Here, we performed a genome-wide haploid genetic screen to identify resistance mechanisms to 3-bromopyruvate (3-BrPA), a drug candidate that inhibits glycolysis in a poorly understood fashion. We identified the SLC16A1 gene product, MCT1, as the main determinant of 3-BrPA sensitivity. MCT1 is necessary and sufficient for 3-BrPA uptake by cancer cells. Additionally, SLC16A1 mRNA levels are the best predictor of 3-BrPA sensitivity and are most elevated in glycolytic cancer cells. Furthermore, forced MCT1 expression in 3-BrPA–resistant cancer cells sensitizes tumor xenografts to 3-BrPA treatment in vivo. Our results identify a potential biomarker for 3-BrPA sensitivity and provide proof of concept that the selectivity of cancer-expressed transporters can be exploited for delivering toxic molecules to tumors.National Institutes of Health (U.S.) (NIH CA103866)Jane Coffin Childs Memorial Fund for Medical Research (Fellowship)National Science Foundation (U.S.) (Fellowship)Howard Hughes Medical Institute (Investigator

The host-guest chemistry of proflavine with cucurbit[6,7,8]urils

The binding of the polyaromatic guest, 3,6-diaminoacridine (Proflavine) to cucurbit[n]uril (CB[n]) where n = 6, 7 and 8 has been studied by fluorescence spectrophotometry and binding constants determined using a least squares fitting method. Titration of CB[8] into a solution of Proflavine results in a 95% decrease in fluorescence up to a CB[8] to Proflavine ratio of 2:1. From the induced fluorescence spectra a binding constant of 1.9 times 107 M- 1 was determined. When Proflavine is titrated into a solution of CB[8] a similar binding constant is calculated (1.3 times 107 M- 1). Titration of CB[6] into a solution of Proflavine yields a decrease in fluorescence of 18-20%, but no binding is observed beyond what is seen within experimental error. Finally, titration of CB[7] into a solution of Proflavine results in an increase in fluorescence (32%) and a blue-shift of the emission wavelength from 509 nm to 485 nm. From the induced fluorescence spectra a binding constant of 1.65 times 107 M- 1 was determined. From 1H NMR it appears that the decrease in fluorescence for Proflavine with CB[6] and CB[8] is due to collisional quenching, whereas the increase in fluorescence with CB[7] may be due to rotational restriction